University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder (PTSD)
17.5.2022 14:05:00 EEST | Business Wire | Press release
The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005065/en/
(Photo: Business Wire)
The trial is being led by principal investigator Mathew Rizzo, M.D., the Reynolds Professor and chair of the UNMC Department of Neurological Sciences and Chief Physician for neurological services at Nebraska Medicine.
The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the U.S. Food and Drug Administration (FDA).
(Clinical Trials.gov Identifier NCT05269459)
“This is our second clinical trial targeting PTSD. We are excited that UNMC’s research team has partnered with us to evaluate our promising drug for this very debilitating condition,” said Sohail R. Zaidi , ANANDA’s Chief Executive Officer. “It is an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options.”
“Advancing evidence-based research into new therapeutics to provide a large PTSD patient population with new innovative treatment options is a key objective for our research team,” Dr. Rizzo said. “We are delighted to be collaborating with ANANDA Scientific on this trial.”
Dr. Rizzo also is the director of the National Institutes of Health’s Great Plains IDeA Clinical and Translational Research Network. He chairs the executive committee of the American Brain Coalition which advocates to advance research for neurological cures.
Dr. Rizzo’s research team will include Jennifer Merickel, Ph.D., Cognitive Neuroscientist and Assistant Professor in the UNMC Department of Neurological Sciences and Brigette Vaughan, an Advanced Practice Registered Nurse, Clinician and Researcher in the UNMC Department of Psychiatry.
This phase II double-blind, placebo controlled, randomized clinical study is planning to enroll 240 participants to provide rigorous clinical and real-world evaluation of the efficacy and safety of Nantheia™ ATL5.
ABOUT NANTHEIA™ ATL5
Nantheia™ ATL5 is an investigational drug that uses cannabidiol in ANANDA’s propriety Liquid Structure delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100mg cannabidiol per softgel capsule.
ABOUT University of Nebraska Medical Center
As Nebraska’s only public academic health sciences center, UNMC is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving the state and its communities through award-winning outreach. UNMC has six colleges and two institutes, serving more than 4,200 students in two dozen programs. Researchers at UNMC perform cutting-edge research in neurological sciences, oncology, infectious disease, and other key areas.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biopharmaceutical company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder (Mt. Sinai and UCLA). The company employs patented delivery technology to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its clinical portfolio. Consistent with its strong research-based data, the company has a growing pipeline of nutraceutical over-the-counter products. ANANDA has successfully launched these products in the U.S., Australia, and the U.K., with expansion into additional markets such as the EU, China, Africa, and other countries in Asia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005065/en/
Contact information
ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 202621.10.2026 13:47:00 EEST | Press release
Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The commercial launch follows Compvide’s participation in the 20th European Meeting on Complement in Human Disease (EMCHD), held September 1–5, 2026, in Cardiff, Wales. Through a scientific presentation, poster, and exhibition, the company shared research highlighting the importance of assay conditions in evaluating complement activity and the effects of complement-targeting therapies. Unlike conventional assays that often use highly diluted serum, CIMED assays use 50% serum. Research presented by Compvide at EMCHD highlighted how serum dilution can influence measurements of complement inhibition, particularly at lower drug concentrations. These findings underscore the importance of assay conditions when evaluating pote
Forrester’s 2027 B2C Marketing, CX, And Digital Predictions: Rising AI Costs Will Force B2C Leaders To Scale Back A Third Of AI Initiatives21.10.2026 11:30:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 B2C marketing, customer experience, and digital predictions, rising AI costs will force B2C marketing leaders to scale back a third of AI initiatives. As AI usage grows and martech vendors increasingly adopt usage-based pricing models, every agent interaction, generated asset, and automated workflow becomes a billable event. As a result, leaders will need to make tougher decisions and focus investments on AI initiatives that deliver measurable business value. Forrester’s Predictions reports deliver forward-looking insights into the signals and trends that will shape the year ahead. Forrester’s consumer marketing, CX, and digital business predictions cover topics including B2C marketing, customer experience, consumer behavior, digital commerce, media and advertising, marketing agencies, content and creative, and trust and privacy. Additional highlights from Forrester’s 2027 B2C marketing, CX, and digital predictions include: CX staffing will
Forrester’s 2027 B2B Go-To-Market Predictions: AI Agents Will Influence 75% of B2B Purchase Decisions21.10.2026 11:30:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 B2B go-to-market predictions, business buyers will increasingly deploy AI agents to handle tasks across the buying process, from supplier discovery and information gathering to contract-renewal analysis. While truly autonomous buying will remain concentrated in high-volume, low-risk, and repeatable purchases, the ubiquity of these agents will require providers to ensure that their systems and sellers can respond with speed, accuracy, and consistency. Forrester’s B2B Predictions reports, covering topics including B2B go-to-market strategy, business buyers, and content and creative, offer forward-looking insights to help executives and their teams anticipate change, reduce uncertainty, and make confident decisions ahead of market shifts. Key highlights from the 2027 B2B go-to-market predictions include: Buyers will double their human interactions to validate AI-generated recommendations. As AI becomes the primary interface for researching prod
Forrester’s 2027 Technology And Security Predictions: AI Will Account For 20% Of All Business Technology Spend21.10.2026 11:30:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 technology and security predictions, CIOs and CISOs will face growing pressure to realize returns on their AI investments in infrastructure, security, digital sovereignty, and emerging technologies. Additionally, with global technology spending forecasted to reach $6.1 trillion in 2027, technology leaders will need to balance AI governance and control with innovation and business agility. Forrester’s Predictions reports offer forward-looking insights into the trends and signals that empower leaders and their teams to think beyond the conventional and ignite bold ideas for the year ahead. Forrester’s technology and security predictions cover topics including AI, automation and robotics, tech leadership, cloud computing, tech infrastructure and operations, enterprise software, software development, cybersecurity and risk, and smart manufacturing and mobility. Key highlights from Forrester’s 2027 technology and security predictions include: A q
LTM Launches BlueVerse™ ValueMesh™ to Help Enterprises Scale AI Across Oracle Transformations21.10.2026 11:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ ValueMesh™, an AI execution fabric designed to help enterprises industrialize AI across the Oracle transformation lifecycle, from strategy and implementation to operations and continuous innovation. BlueVerse™ ValueMesh™ is developed and validated by LTM as part of its Cloud Services expertise. Built on LTM's deep Oracle expertise and BlueVerse™ portfolio, BlueVerse™ ValueMesh™is designed to help enterprises industrialize AI across their Oracle transformation journey. It brings together AI-native delivery, intelligent automation, AI agents, managed services, intelligent business processes, industry solutions, data, and governance in a unified execution model designed to help organizations move beyond fragmented initiatives and isolated pilots and pursue scalable innovation, continuous optimization, and measurable business outcomes across their Oracle estate. At its core, Bl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom